A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer with Curative Intent (ARTEMIDE-Biliary01)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
AstraZeneca
The purpose of this research is to understand if the study drug rilvegostomig (together with chemotherapy) can help to reduce the risk of biliary tract cancer coming back after surgery. We will compare the effect and safety of rilvegostomig and chemotherapy to the standard treatment for biliary cancer after surgery (chemotherapy only).
Enrollment Form
This study is currently enrolling.